NCT06245876
Recruiting
Not Applicable
Lung EpiCheck Biomarkers Development Study
ConditionsLung Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Lung Cancer
- Sponsor
- Nucleix Ltd.
- Enrollment
- 6000
- Locations
- 10
- Primary Endpoint
- Performance
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
This study is part of the development of a non-invasive lung cancer screening test which aim to identify early-stage lung cancer in patients at high risk for lung cancer.
Detailed Description
This is a prospective, multi-center, observational nonsignificant risk study aimed to collect blood and clinical data from primary lung cancer and control subjects to characterize various biomarkers that will discriminate between lung cancer and control subjects.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Performance
Time Frame: Day 1
Performance of the assay in terms of (1) Sensitivity (2) Specificity (3) NPV (negative predictive value) and (4) PPV (positive predictive value).
Study Sites (10)
Loading locations...
Similar Trials
Active, not recruiting
Not Applicable
Determination and Validation of a Multi-analyte Assay for Lung Cancer ScreeningLung CancerNCT04968548Nucleix Ltd.5,000
Unknown
Not Applicable
'Lung Health Check' Biomarker StudyLung CancerCancerNCT04957433Royal Marsden NHS Foundation Trust1,000
Completed
Not Applicable
Biomarkers for Diagnosis of Lung CancerLung CancerLung NeoplasmNCT02050100SK Medical (Beijing) Co., Ltd.300
Recruiting
Not Applicable
Study of Early Cancer Biomarkers in Breath Condensate in Population of Individuals With High-Risk of Lung Cancer Undergoing LDCT Screening.Lung CancerNCT06016569The Institute of Molecular and Translational Medicine, Czech Republic3,200
Recruiting
Phase 3
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint InhibitorsLung CancerNCT05055908Hunan Province Tumor Hospital12,000